Insmed Incorporated INSM
Set alert
At close · Oct 30
After hours · Oct 30, 6:08 PM ET
- YTD
- -35.31%
- 1 year
- -42.03%
- Open
- 113.60
- Prev close
- 111.59
- Mkt cap
- 24.70B
- Vol
- 5.18M
- Avg vol
- 2.92M
- EPS
- -4.10
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 111.97
- High
- 116.37
- Forward P/E
- 150.84
- Beta
- 0.00
- Short ratio
- 4.85
- Inst. own
- 105.63%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 18, 2027
- 50-d avg
- 112.91
- 200-d avg
- 125.67
- 1y target
- 194.23
5D chart
Events in this range
- Oct 29, 2026Earnings: -0.46; estimate -0.38273; surprise -20.19%
Signals (134)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 3:40 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 3:40 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:35 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:30 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:30 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:25 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:25 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:20 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:20 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:15 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:15 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:55 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:55 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:40 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:40 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:35 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:10 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:55 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 1:55 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:50 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:45 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:35 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:20 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:30 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:30 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:20 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:20 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:00 PM | 2 days ago |
| SMA: Bullish | Oct 30, 11:55 AM | 2 days ago |
| SMA: Bearish | Oct 30, 11:45 AM | 2 days ago |
| SMA: Bearish | Oct 30, 11:30 AM | 2 days ago |
| SMA: Bullish | Oct 30, 11:20 AM | 2 days ago |
| SMA: Bearish | Oct 30, 11:10 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:35 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 10:25 AM | 2 days ago |
| SMA: Bearish | Oct 30, 10:15 AM | 2 days ago |
| SMA: Bullish | Oct 30, 9:50 AM | 2 days ago |
| SMA: Bearish | Oct 30, 9:45 AM | 2 days ago |
| RSI: Overbought | Oct 30, 9:30 AM | 2 days ago |
| SMA: Bullish | Oct 29, 3:10 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 3:10 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:00 PM | 3 days ago |
| SMA: Bearish | Oct 29, 1:55 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:20 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:05 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:50 AM | 3 days ago |
| RSI: Overbought | Oct 29, 11:40 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:30 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:20 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:50 AM | 3 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 3 days ago |
| MACD: Buy Signal | Oct 29, 9:30 AM | 3 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 3 days ago |
| SMA: Bearish | Oct 28, 3:55 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 3:55 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:30 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:10 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:10 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 3:10 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:05 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:00 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 2:35 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:25 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:20 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:15 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:55 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:45 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 1:35 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:10 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:05 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:00 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:55 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:10 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 12:10 PM | 4 days ago |
| RSI: Overbought | Oct 28, 11:50 AM | 4 days ago |
| RSI: Overbought | Oct 28, 11:20 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 10:10 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:05 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:05 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:00 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:55 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:45 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 9:45 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:40 AM | 4 days ago |
| MACD: Buy Signal | Oct 27, 3:35 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:30 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:30 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:25 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 3:20 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:10 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:05 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:00 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:55 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:35 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:55 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 1:30 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:20 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:20 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:05 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:05 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:00 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:00 PM | 5 days ago |
| SMA: Bearish | Oct 27, 11:55 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:10 AM | 5 days ago |
| RSI: Overbought | Oct 27, 10:25 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:55 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:55 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:35 AM | 5 days ago |
| SMA: Bearish | Oct 26, 3:55 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:45 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:45 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 3:45 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:40 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:35 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:20 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:10 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 2:35 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:20 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:20 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:00 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:50 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 1:50 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:40 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:20 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 12:40 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:25 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:00 PM | 6 days ago |
| SMA: Bullish | Oct 26, 11:50 AM | 6 days ago |
| SMA: Bearish | Oct 26, 11:30 AM | 6 days ago |
| SMA: Bullish | Oct 26, 11:00 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:30 AM | 6 days ago |
News
2 days ago seekingalpha.com
Insmed Incorporated (INSM) Q3 2026 Earnings Call Transcript
Insmed Incorporated ( INSM ) Q3 2026 Earnings Call October 29, 2026 8:00 AM EDT Company Participants William Lewis - President, CEO & Chairman Sara Bonstein Martina Flammer - Chief Medical Officer…
2 days ago zacks.com
INSM Q3 Earnings Miss, Stock Soars on Sales Beat & Raised Guidance
Insmed's third-quarter revenues surge 268%, fueled by strong Brinsupri sales, prompting a 15% stock rally and higher 2026 sales guidance.
3 days ago marketbeat.com
What Insmed (INSM) Said on Its Q3 Earnings Call
Insmed NASDAQ: INSM reported third-quarter 2026 revenue growth from both of its commercial respiratory products and raised the low end of its full-year revenue guidance for BRINSUPRI and ARIKAYCE.
3 days ago benzinga.com
Alphabet Sinks 11.8%, Small Caps Rally on Strong GDP Growth: Stock Market Today
Alphabet's capex-heavy quarter drags the Nasdaq 100 lower while GDP beats and the Russell 2000 rallies, with three of four large caps rising.
3 days ago zacks.com
Insmed (INSM) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Insmed (INSM) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics…
3 days ago benzinga.com
Huntington Ingalls, Crocs, Carvana, Insmed And Other Big Stocks Moving Higher On Thursday
Stocks rallied on strong earnings and raised guidance, led by Huntington Ingalls, Porch, Teladoc and Crocs, despite the Dow falling 150 points.
3 days ago zacks.com
Insmed (INSM) Reports Q3 Loss, Tops Revenue Estimates
Insmed (INSM) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to a loss of $1.75 per share a year ago.
3 days ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Mesoblast (NASDAQ:MESO) stock rose 16.2% to $15.57 during Thursday's pre-market session. The market value of their outstanding shares is at $1.7 billion. Glaukos (NYSE:GKOS) stock rose 15.75%…
-
3 days ago benzinga.com
Insmed Q3 EPS $(0.46) Misses $(0.43) Estimate, Sales $524.428M Beat $501.350M Estimate
Insmed (NASDAQ:INSM) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate of $(0.43) by 6.98 percent. This is a 73.71 percent increase over losses of $(1.75) per…
-
3 days ago benzinga.com
Insmed Raises FY2026 Sales Guidance from $1.700B-$1.870B to $1.810B-$1.870B vs $1.801B Est
Insmed (NASDAQ:INSM) raises FY2026 sales outlook from $1.700 billion-$1.870 billion to $1.810 billion-$1.870 billion vs $1.801 billion estimate.
3 days ago prnewswire.com
Insmed Reports Third-Quarter 2026 Financial Results and Provides Business Update
—Total Company Revenues of $524.4 Million for the Third Quarter of 2026— —BRINSUPRI ® (brensocatib) Revenues of $400.1 Million for the Third Quarter of 2026, Reflecting 29% Growth Over the Second…
4 days ago defenseworld.net
Citizens Financial Group Inc. RI Makes New Investment in Insmed, Inc. $INSM
Citizens Financial Group Inc. RI acquired a new position in shares of Insmed, Inc. (NASDAQ: INSM) during the third quarter, according to its most recent filing with the Securities and Exchange…
1 week ago benzinga.com
$100 Invested In Insmed 15 Years Ago Would Be Worth This Much Today
Insmed (NASDAQ:INSM) has outperformed the market over the past 15 years by 11.42% on an annualized basis producing an average annual return of 24.03%. Currently, Insmed has a market capitalization of…
1 week ago zacks.com
Insmed (INSM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
-
1 week ago benzinga.com
Morgan Stanley Maintains Overweight on Insmed, Lowers Price Target to $213
Morgan Stanley analyst Matthew Harrison maintains Insmed (NASDAQ:INSM) with a Overweight and lowers the price target from $218 to $213.
1 week ago benzinga.com
Top 3 Health Care Stocks That Could Blast Off In October
Insmed, Axsome Therapeutics and Arrowhead Pharmaceuticals are oversold by RSI, potentially offering undervalued buying opportunities.
1 week ago prnewswire.com
Insmed Appoints Two New Directors to Its Board
—Paul Hudson, Former CEO of Sanofi and Novartis Pharmaceuticals, and Utpal Koppikar, CFO of Verily Health and Veteran Biopharma Finance Leader, Join as New Independent Directors— BRIDGEWATER, N.J.,…
1 week ago prnewswire.com
Insmed Launches BRINSUPRI® Tablets 25 mg (brensocatib hydrate) for the Treatment of Non-Cystic Fibrosis Bronchiectasis in Japan
—BRINSUPRI, a First-in-Disease and First-in-Class Treatment for Patients With Non-Cystic Fibrosis Bronchiectasis (NCFB), Is Now Available by Prescription in Japan— BRIDGEWATER, N.J., Oct. 19, 2026…
2 weeks ago prnewswire.com
Insmed Features the Global Phase 3 PALM Clinical Development Program Evaluating Treprostinil Palmitil Inhalation Powder (TPIP) at CHEST 2026
—Insmed's Largest Parallel-Running Clinical Effort to Date With Four Pivotal Phase 3 Studies Advancing Across Four Progressive Pulmonary Diseases: PALM-PAH, PALM-ILD, PALM-PPF, and PALM-IPF— —One of…
2 weeks ago prnewswire.com
Insmed to Present New Data Across Its Respiratory Portfolio at CHEST 2026 and IDWeek 2026
—Three Late-Breaking Abstracts at CHEST 2026 Deepen Understanding of the Potential of Treprostinil Palmitil Inhalation Powder (TPIP) Across Pulmonary Arterial Hypertension (PAH) and Pulmonary…
2 weeks ago defenseworld.net
Perpetual Ltd Acquires 5,760 Shares of Insmed, Inc. $INSM
Perpetual Ltd raised its holdings in shares of Insmed, Inc. (NASDAQ: INSM) by 164.0% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and…
2 weeks ago benzinga.com
This Adobe Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Analysts downgraded ACGL, ASTS, PS, LNTH and ADBE, cutting ratings and price targets; ASTS target fell to $54 and Adobe’s to $267.
2 weeks ago benzinga.com
This Insmed Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings…
2 weeks ago benzinga.com
This Insmed Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Analysts downgraded UWMC, ACT, ROIV, INSM; ACT’s target fell to $44.
-
2 weeks ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Insmed, Announces $220 Price Target
HC Wainwright & Co. analyst Andrew S. Fein reiterates Insmed (NASDAQ:INSM) with a Buy and announces $220 price target.
3 weeks ago zacks.com
INSM Stock Slides on CFO Exit, Reiterates '26 Sales View
Insmed shares slide after CFO Sara Bonstein's surprise exit, though the company reaffirms 2026 revenue guidance for Brinsupri and Arikayce.
-
3 weeks ago benzinga.com
$100 Invested In Insmed 5 Years Ago Would Be Worth This Much Today
Insmed (NASDAQ:INSM) has outperformed the market over the past 5 years by 17.45% on an annualized basis producing an average annual return of 29.54%. Currently, Insmed has a market capitalization of…
3 weeks ago benzinga.com
Nasdaq 100 Hits Record, Brazil's EWZ Soars 13%: Stock Market Today
Nasdaq 100 hits a record as Brazil's EWZ jumps 13% on Bolsonaro's election upset; ISM services prices hit a four-year high and the 10-year yield tops 5.3%.
3 weeks ago benzinga.com
Insmed Stock Slides — CFO Exit Date Set, 2026 Guidance Reaffirmed
Insmed Inc. (NASDAQ:INSM) shares are trading lower by almost 7% on Monday as traders digest a CFO transition update alongside a slightly softer risk tone.
3 weeks ago benzinga.com
Insmed Stock Slides — CFO Exit Date Set, 2026 Guidance Reaffirmed
Insmed shares slip after CFO Sara Bonstein steps down, reaffirms 2026 financial targets.
3 weeks ago benzinga.com
Insmed Q2 2026 Earnings Call Transcript
Insmed (NASDAQ:INSM) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide real-time…
-
3 weeks ago benzinga.com
Insmed Reaffirms FY26 Revenue Guidance Of $1.25B-$1.40B For BRINSUPRI And $450M- $470M For ARIKAYCE
Reaffirms Full-Year 2026 GuidanceAs Insmed continues to build on its operational excellence and momentum, the Company reaffirms its full-year 2026 financial guidance of revenue in the range of $1.25…
3 weeks ago prnewswire.com
Insmed Announces CFO Transition
— Sara Bonstein Will Step Down as CFO on October 30 After Nearly Seven Years of Dedicated Leadership — — Company Reaffirms Full-Year 2026 Financial Guidance — — Company Announces Third-Quarter 2026…
-
1 month ago benzinga.com
Barclays Maintains Overweight on Insmed, Lowers Price Target to $207
Barclays analyst Eliana Merle maintains Insmed (NASDAQ:INSM) with a Overweight and lowers the price target from $237 to $207.
1 month ago benzinga.com
$1000 Invested In Insmed 15 Years Ago Would Be Worth This Much Today
Insmed (NASDAQ:INSM) has outperformed the market over the past 15 years by 11.06% on an annualized basis producing an average annual return of 24.7%. Currently, Insmed has a market capitalization of…
1 month ago marketbeat.com
3 Healthcare Stocks Showing Why the Sector Still Has Momentum
The healthcare sector has performed fairly well so far in 2026 due to several factors: GLP-1 medications continue to drive new business and interest, while groundbreaking AI applications help enhance…
1 month ago zacks.com
FDA Accepts Insmed's Filing Seeking Label Expansion for Arikayce
INSM's Arikayce label expansion gets FDA priority review, potentially broadening its use in newly diagnosed MAC lung disease.
1 month ago seekingalpha.com
Insmed: Expensive Stock, But Discount To Recent Highs Makes Bull Case
Insmed is rated Buy, driven by Brinsupri's blockbuster launch and strong TPIP Phase 2b data. Brinsupri generated $517m in 1H 2026, faces minimal competition, and targets $7bn+ peak sales with…
-
1 month ago benzinga.com
The FDA Accepts Insmed's Supplemental New Drug Application For Review Of Arikayce (Amikacin Liposome Inhalation Suspension) For Mycobacterium Avium Complex Lung Disease As Part Of Combination Antibacterial Drug Regimen, With Target Action Date Of January 28, 2027
Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases,…
-
1 month ago benzinga.com
Roth Capital Reiterates Buy on Insmed, Lowers Price Target to $198
Roth Capital analyst Adam Walsh reiterates Insmed (NASDAQ:INSM) with a Buy and lowers the price target from $212 to $198.
1 month ago benzinga.com
Here's How Much $100 Invested In Insmed 5 Years Ago Would Be Worth Today
Insmed (NASDAQ:INSM) has outperformed the market over the past 5 years by 24.42% on an annualized basis producing an average annual return of 35.99%. Currently, Insmed has a market capitalization of…
-
2 months ago benzinga.com
If You Invested $1000 In Insmed Stock 10 Years Ago, You Would Have This Much Today
Insmed (NASDAQ:INSM) has outperformed the market over the past 10 years by 10.74% on an annualized basis producing an average annual return of 24.29%. Currently, Insmed has a market capitalization of…
2 months ago benzinga.com
Biotech Is Booming, But These 2 Stocks Missed the Memo
The iShares Biotechnology ETF is trading at new highs and 18 out of its top 20 constituents are green for the year.
-
2 months ago benzinga.com
JP Morgan Maintains Overweight on Insmed, Lowers Price Target to $175
JP Morgan analyst Jessica Fye maintains Insmed (NASDAQ:INSM) with a Overweight and lowers the price target from $179 to $175.
-
2 months ago benzinga.com
Truist Securities Reiterates Buy on Insmed, Raises Price Target to $195
Truist Securities analyst Danielle Brill reiterates Insmed (NASDAQ:INSM) with a Buy and raises the price target from $185 to $195.
-
2 months ago benzinga.com
$1000 Invested In Insmed 5 Years Ago Would Be Worth This Much Today
Insmed (NASDAQ:INSM) has outperformed the market over the past 5 years by 29.76% on an annualized basis producing an average annual return of 41.43%. Currently, Insmed has a market capitalization of…
-
2 months ago benzinga.com
Guggenheim Maintains Buy on Insmed, Lowers Price Target to $205
Guggenheim analyst Vamil Divan maintains Insmed (NASDAQ:INSM) with a Buy and lowers the price target from $207 to $205.
-
2 months ago benzinga.com
Wells Fargo Maintains Overweight on Insmed, Raises Price Target to $169
Wells Fargo analyst Benjamin Burnett maintains Insmed (NASDAQ:INSM) with a Overweight and raises the price target from $161 to $169.
-
2 months ago benzinga.com
Evercore ISI Group Maintains Outperform on Insmed, Raises Price Target to $170
Evercore ISI Group analyst Josh Schimmer maintains Insmed (NASDAQ:INSM) with a Outperform and raises the price target from $160 to $170.
2 months ago benzinga.com
S&P 500, Dow Fall as Brent Jumps 4%, SanDisk Trims Losses: Stock Market Today
Crude's rebound on Yemen strikes pulled U.S. equities off record highs Thursday, while SanDisk pared losses despite record margins.